

The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

Claims 1-42. (Cancelled).

43.(Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 57, comprising Δ^9 -tetrahydrocannabinol, and up to 15 percent by weight of an organic solvent, said Δ^9 -tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said Δ^9 -tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (± 0.008) to 5.940% w/w (± 0.191).

44-45. (Canceled)

46. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 43 wherein said organic solvent comprises ethanol.

47. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 43 wherein said solution consists essentially of said hydrofluoroalkane and said Δ^9 -tetrahydrocannabinol.

48. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 43 wherein said stable composition is surfactant free.

49. (Canceled)

50. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 57, comprising up to 15 percent by weight of an organic solvent, said tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (± 0.008) to 5.940% w/w (± 0.191).

51. (Canceled)

52. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 50 wherein said tetrahydrocannabinol is a pharmaceutically acceptable salt of said tetrahydrocannabinol.

53. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 50 wherein said organic solvent comprises ethanol.

54. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 50 wherein said solution consists essentially of said hydrofluoroalkane and said tetrahydrocannabinol.

55. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 50 wherein said stable composition is surfactant free.

56. (Canceled)

57. (Previously Presented) An aerosol-dispensable pharmaceutical composition comprising: tetrahydrocannabinol and hydrofluoroalkane, wherein the composition is aerosol-dispensable.

58. (Previously Presented) The aerosol-dispensable pharmaceutical composition of claim 57, comprising up to 15 percent by weight of an organic solvent, said tetrahydrocannabinol and said

organic solvent being dissolved in said hydrofluoroalkane to form a stable composition.

59. (Previously Presented) An aerosolized pharmaceutical composition comprising: respirable droplets comprising a tetrahydrocannabinol.

60. (Previously Presented) The aerosolized pharmaceutical composition of claim 59, comprising a hydrofluoroalkane.

61. (New) A method of aerosolizing a tetrahydrocannabinol, comprising:
dissolving a tetrahydrocannabinol in a hydrofluoroalkane and forming a stable pharmaceutical composition;
aerosolizing the stable pharmaceutical composition into respirable droplets comprising the tetrahydrocannabinol.

62. (New) The method of claim 61, wherein the tetrahydrocannabinol is Δ^9 -tetrahydrocannabinol.

63. (New) A non-CFC aerosol-dispensable pharmaceutical composition comprising tetrahydrocannabinol (THC).